ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL24778
CHEMBL24778
Compound Name SILODOSIN
ChEMBL Synonyms SILODOSIN | RAPAFLO
Max Phase 4 (Approved)
Trade Names RAPAFLO
Molecular Formula C25H32F3N3O4

Additional synonyms for CHEMBL24778 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(=O)N)NCCOc3ccccc3OCC(F)(F)F
Standard InChI InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-1 ...
Download InChI
Standard InChI Key PNCPYILNMDWPEY-QGZVFWFLSA-N

Sources

  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL24778

Molecule Features

CHEMBL24778 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Alpha-1a adrenergic receptor antagonist Alpha-1a adrenergic receptor DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Kidney CalculiD007669EFO:0003845kidney stone3ClinicalTrials
ProstatitisD011472EFO:0003830prostatitis2ClinicalTrials
Premature EjaculationD0616862ClinicalTrials
Prostatic HyperplasiaD011470EFO:0000284benign prostatic hyperplasia4ATC
ClinicalTrials
DailyMed
DailyMed
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma3ClinicalTrials

Clinical Data

ClinicalTrials.gov SILODOSIN
The Cochrane Collaboration SILODOSIN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL24778. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL223 Alpha-1d adrenergic receptor Homo sapiens 1.000
CHEMBL229 Alpha-1a adrenergic receptor Homo sapiens 1.000
CHEMBL232 Alpha-1b adrenergic receptor Homo sapiens 1.000

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL223 Alpha-1d adrenergic receptor Homo sapiens 1.000
CHEMBL232 Alpha-1b adrenergic receptor Homo sapiens 1.000
CHEMBL229 Alpha-1a adrenergic receptor Homo sapiens 1.000

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
495.5 495.2345 3.07 13 97.05 BASE


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
6 3 0 7 4 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- 8.78 3.04 1.59 2 35 0.37

Structural Alerts

There are 1 structural alerts for CHEMBL24778. To view alerts please click here.

Compound Cross References

ATC G - GENITO URINARY SYSTEM AND SEX HORMONES
G04 - UROLOGICALS
G04C - DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04CA - Alpha-adrenoreceptor antagonists
G04CA04 - silodosin

ChemSpider ChemSpider:PNCPYILNMDWPEY-QGZVFWFLSA-N
DailyMed silodosin
Wikipedia Silodosin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL24778



ACToR 160970-54-7
BindingDB 50160154
ChEBI 135929
ChemicalBook CB42129460 CB31463425
DrugBank DB06207
DrugCentral 4151
eMolecules 31231716
EPA CompTox Dashboard DTXSID40167045
FDA SRS CUZ39LUY82
Guide to Pharmacology 493
IBM Patent System 41603A9DFAD9D54C5CF0BC6450F99851
MolPort MolPort-006-167-837
Nikkaji J786.452C
PubChem 5312125
PubChem: Drugs of the Future 12014894
PubChem: Thomson Pharma 14835413 14810706
SureChEMBL SCHEMBL136973
ZINC ZINC000003806063

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/PNCPYILNMDWPEY-QGZVFWFLSA-N spacer
spacer